Department of General Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Crit Rev Oncol Hematol. 2020 Mar;147:102888. doi: 10.1016/j.critrevonc.2020.102888. Epub 2020 Jan 30.
The purpose of this study was to analyze the efficacy of PARP inhibitor on solid tumors.
For this study, the following databases were searched for articles published from its inception until July 2019: PubMed, Web of Science, EBSCO, and Cochrane library, of which the main conclusion was the overall survival (OS) and progression-free survival (PFS).
We conducted a meta-analysis and the results showed that PARP inhibitor increased the patients' PFS (HR: 0.51, p < 0.001), PFS with BRCA1/2 mutations (HR: 0.32, p < 0.001), OS (HR: 0.74, p < 0.001), OS with BRCA1/2 mutations (HR: 0.78, p = 0.03), complete response (CR) (RR: 1.89, p = 0.10), partial response (PR) (RR: 1.34, p = 0.01), overall response rate (ORR) (RR: 1.42, p = 0.001) respectively. The main adverse events (AEs) observed were decreased appetite.
PARP inhibitors may prolong survival. PARP inhibitors were more favorable for BRCA1/2 mutations in ovarian cancer patients. Additionally, the overall safety factor was controllable.
本研究旨在分析聚腺苷二磷酸核糖聚合酶（PARP）抑制剂对实体瘤的疗效。
本研究检索了从建库至 2019 年 7 月发表的文章，使用的数据库有 PubMed、Web of Science、EBSCO 和 Cochrane library，主要结论为总生存期（OS）和无进展生存期（PFS）。
我们进行了荟萃分析，结果表明 PARP 抑制剂增加了患者的 PFS（HR：0.51，p < 0.001）、BRCA1/2 突变患者的 PFS（HR：0.32，p < 0.001）、OS（HR：0.74，p < 0.001）、BRCA1/2 突变患者的 OS（HR：0.78，p = 0.03）、完全缓解（CR）（RR：1.89，p = 0.10）、部分缓解（PR）（RR：1.34，p = 0.01）、总缓解率（ORR）（RR：1.42，p = 0.001）。主要不良事件（AE）为食欲减退。
PARP 抑制剂可能延长生存时间。PARP 抑制剂对卵巢癌患者的 BRCA1/2 突变更有利。此外，整体安全性因素是可控的。
